Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results

類似資料

• Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
  著者:: Cortes, Jorge E., 等
  出版事項: (2018)
• Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
  著者:: Cortes, Jorge E., 等
  出版事項: (2020)
• Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
  著者:: Kent, Andrew, 等
  出版事項: (2020)
• Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
  著者:: Heuser, Michael, 等
  出版事項: (2021)
• Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
  著者:: Gondek, Lukasz P., 等
  出版事項: (2008)